“U.S. Antinuclear Antibody (ANA) Testing Market” Top Key Companies 2018: Alere, Bio-Rad Laboratories and ThermoFisher Scientific

Trending research title” U.S. Anti-nuclear Antibody Test Market – Industry Trends and Forecast to 2025” added by Data Bridge Market Research. The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection are boosting the growth of the U.S. anti-nuclear antibody test market.

U.S. Anti-nuclear Antibody Test Market will reach USD 846.40 million by 2025 from USD 473.10 million in 2017 with a CAGR of 7.6% in the forecast period of 2018 to 2025.

Click here for Free Sample Report with Discount on Full Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=u-s-antinuclear-antibody-test-market

Covered in this report

The report covers the present scenario and the growth prospects of the U.S. anti-nuclear antibody test market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

The key market players for U.S. anti-nuclear antibody test market are listed below:

• Bio-Rad Laboratories, Inc.
• Alere, Inc.
• Trinity Biotech
• Thermo Fisher Scientific Inc.
• Antibodies Inc.
• EUROIMMUN AG
• Immuno Concepts

Any specific requirements are you looking for? Ask to your Industry Experts @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-transradial-access-market

The market is further segmented into:
• Product
• Test
• Disease
• End-user

The U.S. anti-nuclear antibody test market is segmented on the basis of product, test, disease and end-user. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.

The U.S. anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the U.S. anti-nuclear antibody test market with 50.2% market share and is expected to reach USD 432.80 million by 2025, with the highest CAGR of 7.9% in the forecast period 2018 to 2025.

The U.S. anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, Indirect Immunofluorescence is expected to dominate the U.S. anti-nuclear antibody test market with 44.0% market share and is expected to reach USD 347.13 million by 2025, with the CAGR of 6.6% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 8.9% in the forecast period, and is expected to reach USD 217.89 million in 2025 from USD 110.70 million in 2017.

The U.S. anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, Systemic Lupus Erythematosus is expected to dominate the U.S. anti-nuclear antibody test market with 26.2% market share and is expected to reach USD 239.47 million by 2025, at the highest CAGR of 8.8% in the forecast period 2018 to 2025.

The U.S. anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the U.S. anti-nuclear antibody test market with 45.9% market share and is expected to reach USD 396.88 million by 2025, at the highest CAGR of 8.0% in the forecast period 2018 to 2025.

Read more about U.S. Anti-nuclear Antibody Test Market Report Visit @ http://databridgemarketresearch.com/reports/u-s-antinuclear-antibody-test-market/

TABLE OF CONTENTS

1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. YEARS CONSIDERED FOR THE STUDY
2.3. CURRENCY AND PRICING
2.4. RESEARCH METHODOLOGY
2.5. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6. SECONDARY SOURCES
2.7. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. INCREASING INCIDENCE OF AUTOIMMUNE DISEASES
3.1.2. RISING MEDICAL INSURANCE
3.1.3. RISE IN GOVERNMENT HEALTHCARE PROTECTION
3.2. RESTRAINTS
3.2.1. STRICT REGULATION FOR PRODUCT APPROVAL
3.3. OPPORTUNITIES
3.3.1. INCREASING GROWTH IN HEALTHCARE EXPENDITURE
3.3.2. LABORATORY AUTOMATION FAVORS THE MARKET
3.4. CHALLENGES
3.4.1. LACK OF SKILLED PROFESSIONALS
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT
6.1. OVERVIEW
6.2. ASSAY KITS & REAGENTS
6.3. SYSTEMS
6.4. SOFTWARE
7. U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST
7.1. OVERVIEW
7.2. INDIRECT IMMUNOFLUORESCENCE
7.3. ELISA
7.4. MULTIPLEX TESTING
8. U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE
8.1. OVERVIEW
8.2. RHEUMATOID ARTHRITIS
8.3. SYSTEMIC LUPUS ERYTHEMATOSUS
8.4. SJÖGREN’S SYNDROME
8.5. SCLERODERMA
8.6. POLYMYOSITIS
8.7. OTHERS
9. U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER
9.1. OVERVIEW
9.2. HOSPITALS
9.3. CLINICS
9.4. PHYSICIAN OFFICE LABORATORIES
9.5. OTHERS
10. U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, COMPANY LANDSCAPE
10.1. COMPANY SHARE ANALYSIS: NORTH AMERICA
11. COMPANY PROFILES
11.1. THERMO FISHER SCIENTIFIC INC.
11.1.1. COMPANY OVERVIEW
11.1.2. THERMO FISHER SCIENTIFIC INC.:REVENUE ANALYSIS
11.1.3. PRODUCT PORTFOLIO
11.1.4. RECENT DEVELOPMENTS
11.2. MERCK KGAA
11.2.1. COMPANY OVERVIEW
11.2.2. MERCK KGAA: REVENUE ANALYSIS
11.2.3. PRODUCT PORTFOLIO
11.2.4. RECENT DEVELOPMENTS
11.3. ALERE INC.
11.3.1. COMPANY OVERVIEW
11.3.2. ALERE INC.: REVENUE ANALYSIS
11.3.3. PRODUCT PORTFOLIO
11.3.4. RECENT DEVELOPMENTS
11.4. TRINITY BIOTECH
11.4.1. COMPANY OVERVIEW
11.4.2. TRINITY BIOTECH: COMPANY OVERVIEW
11.4.3. PRODUCT PORTFOLIO
11.4.4. RECENT DEVELOPMENTS
11.5. ANTIBODIES INC.
11.5.1. COMPANY OVERVIEW
11.5.2. ANTIBODIES INC.: REVENUE ANALYSIS
11.5.3. PRODUCT PORTFOLIO
11.5.4. RECENT DEVELOPMENTS
11.6. BIO-RAD LABORATORIES, INC.
11.6.1. COMPANY OVERVIEW
11.6.2. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
11.6.3. PRODUCT PORTFOLIO
11.6.4. RECENT DEVELOPMENTS
11.7. EUROIMMUN AG (A SUBSIDIARY OF PERKINELMER INC.)
12. RELATED REPORTS

Browse Detailed TOC, Tables and Figures @ http://databridgemarketresearch.com/toc/?dbmr=u-s-antinuclear-antibody-test-market

Related Report

Global Medical Aesthetics Market – Industry Trends and Forecast to 2024

Global Medical Aesthetic Market, By Product Type (Aesthetic Laser Devices, Energy Devices, Skin Tightening and Body Contouring Devices, Aesthetic Implants, Facial Aesthetic Devices), By Applications (Anti Aging and Wrinkles, Facial & Skin Rejuvenation, Vascular Lesions, Body shaping & cellulite, Breast Enhancement, Scars, Pigment Lesions, Reconstructive Surgery, Tattoo Removal, Hair Removal, Psoriasis & Vitilgo, Skin Surgery, Skin Tightening), By End-User (Hospitals , Dermatology Clinics, Cosmetic Centers, Medical Spas & Beauty Center), By Distribution Channel (Direct Tenders, Retail), By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2024

Report Access: http://databridgemarketresearch.com/reports/global-medical-aesthetics-market/

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.